Advertisement

Investigational New Drugs

, Volume 31, Issue 5, pp 1217–1227 | Cite as

Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

  • Ivana GojoEmail author
  • Alexander Perl
  • Selina Luger
  • Maria R. Baer
  • Kelly J. Norsworthy
  • Kenneth S. Bauer
  • Michael Tidwell
  • Stephanie Fleckinger
  • Martin Carroll
  • Edward A. Sausville
PHASE I STUDIES

Summary

Background The PI3K-Akt pathway is frequently activated in acute leukemias and represents an important therapeutic target. UCN-01 and perifosine are known to inhibit Akt activation. Methods The primary objective of this phase I study was to determine the maximum tolerated dose (MTD) of UCN-01 given in combination with perifosine in patients with advanced acute leukemias and myelodysplastic syndrome. Secondary objectives included safety, pharmacokinetics, pharmacodynamics, and efficacy. Perifosine 150 mg every 6 h was given orally on day 1 followed by 100 mg once a day continuously in 28-day cycles. UCN-01 was given intravenously over 3 h on day 4 at three dose levels (DL1 = 40 mg/m2; DL2 = 65 mg/m2; DL3 = 90 mg/m2). Results Thirteen patients were treated (DL1, n = 6; DL2, n = 4; DL3, n = 3) according to a traditional “3 + 3” design. Two patients at the DL3 experienced dose-limiting toxicity including grade 3–4 pericardial effusion, hypotension, hyperglycemia, hyperkalemia, constitutional symptoms and grade 5 pneumonitis. Other frequent toxicities were grade 1–2 nausea, diarrhea, vomiting, fatigue and hyperglycemia. The MTD was determined to be UCN-01 65 mg/m2 with perifosine 100 mg a day. No appreciable direct Akt inhibition could be demonstrated in patients’ mononuclear cells using Western blot, however, reduced phosphorylation of the downstream target ribosomal protein S6 in leukemic blasts was noted by intracellular flow cytometry. No objective responses were observed on this study. Conclusion UCN-01 and perifosine can be safely administered, but this regimen lacked clinical efficacy. This approach may have failed because of insufficient Akt inhibition in vivo.

Keywords

Acute leukemia Akt inhibition UCN-01 Perifosine 

Notes

Acknowledgments

This work was supported in part by National Cancer Institute Cooperative Agreement UO-1 CA062487 (I.G. and E.A.S.), and the National Center for Research Resources grant M01 RR 16500 to the University of Maryland General Clinical Research Center. Keryx/AOI Pharmaceuticals, Inc. provided support for pharmacokinetic and pharmacodynamics studies (M.C and K.S.B.). The results of this study were in part presented at the American Society of Hematology meeting 2011 (abstract #1557).

Conflict of interest

The authors declare that they do not have further conflict of interest.

Ethical standards

All patients provided written, informed consent. The final study protocol, amendments, and informed consent were approved by the Institutional Review Board of the each participating center. The study was conducted in accordance with the Declaration of Helsinki and in compliance with International Conference on Harmonization Good Clinical Practice Guidelines.

References

  1. 1.
    Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV, Cheng JQ (2005) AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci J Virtual Libr 10:975–987CrossRefGoogle Scholar
  2. 2.
    Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA (2009) Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 18(9):1333–1349. doi: https://doi.org/10.1517/14728220903136775 CrossRefGoogle Scholar
  3. 3.
    Martelli AM, Tabellini G, Bortul R, Tazzari PL, Cappellini A, Billi AM, Cocco L (2005) Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol Histopathol 20(1):239–252PubMedGoogle Scholar
  4. 4.
    Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwable J, Buerger H, Muller-Tidow C, Choudhary C, McMahon M, Berdel WE, Serve H (2005) Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 65(21):9643–9650. doi: https://doi.org/10.1158/0008-5472.CAN-05-0422 CrossRefGoogle Scholar
  5. 5.
    Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C, Recher C (2009) The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 23(6):1029–1038. doi: https://doi.org/10.1038/leu.2008.395 CrossRefGoogle Scholar
  6. 6.
    Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M (2006) Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108(7):2358–2365. doi: https://doi.org/10.1182/blood-2006-02-003475 CrossRefGoogle Scholar
  7. 7.
    Min YH, Cheong JW, Kim JY, Eom JI, Lee ST, Hahn JS, Ko YW, Lee MH (2004) Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 64(15):5225–5231. doi: https://doi.org/10.1158/0008-5472.CAN-04-0174 CrossRefGoogle Scholar
  8. 8.
    Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broet P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah N, Witz F, Dreyfus F, Mayeux P, Lacombe C, Bouscary D (2007) Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 110(3):1025–1028. doi: https://doi.org/10.1182/blood-2006-12-061283 CrossRefGoogle Scholar
  9. 9.
    Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102(3):972–980. doi: https://doi.org/10.1182/blood-2002-11-3429 CrossRefGoogle Scholar
  10. 10.
    Jotta PY, Ganazza MA, Silva A, Viana MB, da Silva MJ, Zambaldi LJ, Barata JT, Brandalise SR, Yunes JA (2010) Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 24(1):239–242. doi: https://doi.org/10.1038/leu.2009.209 CrossRefGoogle Scholar
  11. 11.
    Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL, Cherian C, Devidas M, Linda SB, Taub JW, Matherly LH (2009) The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Leukemia 23(8):1417–1425. doi: https://doi.org/10.1038/leu.2009.64 CrossRefGoogle Scholar
  12. 12.
    Morishita N, Tsukahara H, Chayama K, Ishida T, Washio K, Miyamura T, Yamashita N, Oda M, Morishima T (2011) Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 59(1):83–89. doi: https://doi.org/10.1002/pbc.24034
  13. 13.
    Sun J, Pedersen M, Ronnstrand L (2008) Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit. J Biol Chem 283(41):27444–27451. doi: https://doi.org/10.1074/jbc.M709703200 CrossRefGoogle Scholar
  14. 14.
    Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D (2010) Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95(5):819–828. doi: https://doi.org/10.3324/haematol.2009.013797 CrossRefGoogle Scholar
  15. 15.
    Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, Larson R, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman LB, Hunger SP, Sallan SE, Look AT (2009) High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114(3):647–650. doi: https://doi.org/10.1182/blood-2009-02-206722 CrossRefGoogle Scholar
  16. 16.
    Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098–1101. doi: https://doi.org/10.1126/science.1106148 CrossRefGoogle Scholar
  17. 17.
    Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7):1261–1274. doi: https://doi.org/10.1016/j.cell.2007.06.009 CrossRefGoogle Scholar
  18. 18.
    Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM (2009) A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 15(21):6732–6739. doi: https://doi.org/10.1158/1078-0432.CCR-09-0842 CrossRefGoogle Scholar
  19. 19.
    Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B (2005) Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105(6):2527–2534. doi: https://doi.org/10.1182/blood-2004-06-2494 CrossRefGoogle Scholar
  20. 20.
    Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14(9):2756–2762. doi: https://doi.org/10.1158/1078-0432.CCR-07-1372
  21. 21.
    Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O’Brien S, Andreeff M, Giles FJ (2006) Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12(17):5165–5173. doi: https://doi.org/10.1158/1078-0432.CCR-06-0764 CrossRefGoogle Scholar
  22. 22.
    Sato S, Fujita N, Tsuruo T (2002) Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21(11):1727–1738. doi: https://doi.org/10.1038/sj.onc.1205225 CrossRefGoogle Scholar
  23. 23.
    Hahn M, Li W, Yu C, Rahmani M, Dent P, Grant S (2005) Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 4(3):457–470. doi: https://doi.org/10.1158/1535-7163.MCT-04-0137
  24. 24.
    Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM (2008) Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 22(1):147–160. doi: https://doi.org/10.1038/sj.leu.2404980 CrossRefGoogle Scholar
  25. 25.
    Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S, Grant S (2005) Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65(6):2422–2432. doi: https://doi.org/10.1158/0008-5472.CAN-04-2440 CrossRefGoogle Scholar
  26. 26.
    Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA, Martelli AM (2008) Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res 68(22):9394–9403. doi: https://doi.org/10.1158/0008-5472.CAN-08-2815 CrossRefGoogle Scholar
  27. 27.
    Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, Ferreira-Gonzalez A, Dent P, Grant S (2009) The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood 114(20):4507–4516. doi: https://doi.org/10.1182/blood-2008-09-177881 CrossRefGoogle Scholar
  28. 28.
    Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W (2006) Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107(6):2517–2524. doi: https://doi.org/10.1182/blood-2005-08-3351 CrossRefGoogle Scholar
  29. 29.
    Takahashi I, Saitoh Y, Yoshida M, Sano H, Nakano H, Morimoto M, Tamaoki T (1989) UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J Antibiot 42(4):571–576CrossRefGoogle Scholar
  30. 30.
    Tse AN, Carvajal R, Schwartz GK (2007) Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 13(7):1955–1960. doi: https://doi.org/10.1158/1078-0432.CCR-06-2793 CrossRefGoogle Scholar
  31. 31.
    Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK (2004) In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res 10(15):5242–5252. doi: https://doi.org/10.1158/1078-0432.CCR-03-0534 CrossRefGoogle Scholar
  32. 32.
    Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G (2004) A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10(22):7450–7456. doi: https://doi.org/10.1158/1078-0432.CCR-03-0406 CrossRefGoogle Scholar
  33. 33.
    Edelman MJ, Bauer KS Jr, Wu S, Smith R, Bisacia S, Dancey J (2007) Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin Cancer Res 13(9):2667–2674. doi: https://doi.org/10.1158/1078-0432.CCR-06-1832 CrossRefGoogle Scholar
  34. 34.
    Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, World Health Organization international working group (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96(12):3671–3674PubMedGoogle Scholar
  35. 35.
    Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21(24):4642–4649. doi: https://doi.org/10.1200/JCO.2003.04.036 CrossRefGoogle Scholar
  36. 36.
    Perl AE, Kasner MT, Shank D, Luger SM, Carroll M (2012) Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res 18(6):1716–1725. doi: https://doi.org/10.1158/1078-0432.CCR-11-2346
  37. 37.
    Bauer KS, Lush RM, Rudek MA, Shih C, Sausville E, Figg WD (2000) A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomed Chromatogr 14(5):338–343. doi: https://doi.org/10.1002/1099-0801(200008)14:5%3C338::AID-BMC993%3E3.0.CO;2-6
  38. 38.
    Woo EW, Messmann R, Sausville EA, Figg WD (2001) Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 759(2):247–257CrossRefGoogle Scholar
  39. 39.
    Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JH, Beijnen JH, ten Bokkel Huinink WW (2002) Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38(12):1615–1621CrossRefGoogle Scholar
  40. 40.
    Marvin J, Swaminathan S, Kraker G, Chadburn A, Jacobberger J, Goolsby C (2011) Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML. Blood 117(15):e120–e130. doi: https://doi.org/10.1182/blood-2010-10-316026 CrossRefGoogle Scholar
  41. 41.
    Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J (1997) D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33(3):442–446CrossRefGoogle Scholar
  42. 42.
    Pei XY, Dai Y, Rahmani M, Li W, Dent P, Grant S (2005) The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. Clin Cancer Res 11(12):4589–4600. doi: https://doi.org/10.1158/1078-0432.CCR-04-2346 CrossRefGoogle Scholar
  43. 43.
    Altman JK, Sassano A, Platanias LC (2011) Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2(6):510–517CrossRefGoogle Scholar
  44. 44.
    Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D (2010) Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16(22):5424–5435. doi: https://doi.org/10.1158/1078-0432.CCR-10-1102 CrossRefGoogle Scholar
  45. 45.
    Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA (2012) Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 3(4):371–394CrossRefGoogle Scholar
  46. 46.
    Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J (2012) The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 26(6):1195–1202. doi: https://doi.org/10.1038/leu.2011.339
  47. 47.
    Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB (2012) Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126(1):47–53CrossRefGoogle Scholar
  48. 48.
    Guidetti A, Locatelli S, Viviani S, Dodero A, Farina L, Russo D, Bulian P, Sorasio R, Nicola MD, Corradini P, Anichini A, Gianni AM, Carlo-Stella C (2011) Phosphorylation levels of extracellular-signal regulated kinase (ERK) and AKT in circulating lymphocytes predict response to targeted therapy with kinase inhibitors in refractory/relapsed Hodgkin lymphoma patients. ASH Annual Meeting Abstracts 118(21):3705Google Scholar
  49. 49.
    Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KC (2012) Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol 158(4):472–480CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ivana Gojo
    • 1
    • 4
    Email author
  • Alexander Perl
    • 2
  • Selina Luger
    • 2
  • Maria R. Baer
    • 1
  • Kelly J. Norsworthy
    • 1
  • Kenneth S. Bauer
    • 1
    • 3
  • Michael Tidwell
    • 1
  • Stephanie Fleckinger
    • 1
  • Martin Carroll
    • 2
  • Edward A. Sausville
    • 1
  1. 1.University of Maryland Marlene and Stewart Greenebaum Cancer CenterBaltimoreUSA
  2. 2.University of Pennsylvania Abramson Cancer CenterPhiladelphiaUSA
  3. 3.University of Maryland School of PharmacyBaltimoreUSA
  4. 4.The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUSA

Personalised recommendations